Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

Roberta Rosa; Vincenzo Damiano; Luigi Formisano; Lucia Nappi; Roberta Marciano; Bianca Maria Veneziani; Sabino De Placido; Roberto Bianco

doi:10.4161/onci.25123

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma

Oncoimmunology. 2013 Aug 1;2(8):e25123. doi: 10.4161/onci.25123. Epub 2013 May 28.

Authors

Roberta Rosa¹, Vincenzo Damiano, Luigi Formisano, Lucia Nappi, Roberta Marciano, Bianca Maria Veneziani, Sabino De Placido, Roberto Bianco

Affiliation

¹ Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica; Università di Napoli "Federico II"; Naples, Italy.

Abstract

The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical trials investigating the combination of mTOR inhibitors with TLR9 agonists in RCC patients have been performed to date. Our results may pave the way to translate this combinatorial approach to the clinical setting.

Keywords: TLR9; everolimus; mTOR; microenvironment; renal cell carcinoma.